1h Free Analyst Time
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).Speak directly to the analyst to clarify any post sales queries you may have.
Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 40 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 4, 17 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively. Report covers products from therapy areas Infectious Disease, Gastrointestinal, Oncology, Central Nervous System, Respiratory, Immunology, Cardiovascular, Genito Urinary System And Sex Hormones, Dermatology, Undisclosed, Ear Nose Throat Disorders, Musculoskeletal Disorders and Other Diseases which include indications Coronavirus Disease 2019 (COVID-19), Non-Alcoholic Steatohepatitis (NASH), Autoimmune Hepatitis, Inflammation, Non Alcoholic Fatty Liver Disease (NAFLD), Allergic Rhinitis, Bacterial Sepsis, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Dengue Fever, Influenza A Virus, H1N1 Subtype Infections, Kidney Fibrosis, Liver Fibrosis, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Pain, Respiratory Syncytial Virus (RSV) Infections, Sepsis, Solid Tumor, Acute Ischemic Stroke, Acute Lung Injury, Acute On Chronic Liver Failure (ACLF), Allergic Asthma, Alzheimer's Disease, Atherosclerosis, Bronchopulmonary Dysplasia, Chronic Asthma, Chronic Liver Disease, Chronic Obstructive Pulmonary Disease (COPD), Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), Contact Dermatitis, Coronavirus Disease 2019 (COVID-19) Pneumonia, Crohn's Disease (Regional Enteritis), Cyst, Drug Addiction, Endotoxemia, Escherichia coli Infections, Follicular Lymphoma, Food Allergy, Hearing Disorders, Human Papillomavirus (HPV) Associated Cancer, Inflammatory Bowel Disease, Influenza A Virus, H5N1 Subtype Infections, Influenzavirus B Infections, Intracerebral Hemorrhage, Kidney Disease (Nephropathy), Low Back Pain, Lung Cancer, Marginal Zone B-cell Lymphoma, Merkel Cell Carcinoma, Migraine, Multiple Sclerosis, Myocardial Infarction, Nasal Congestion, Necrotizing Enterocolitis, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Post-Operative Pain, Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Rhinovirus Infections, Schistosomiasis, Soft Tissue Sarcoma, Unspecified, Unspecified B-Cell Lymphomas, Unspecified Cancer, Unspecified Dermatological Disorders, Unspecified Infectious Diseases, Unspecified Rare Disease and Viral Respiratory Tract Infection.
The latest report Toll Like Receptor 4 - Drugs In Development, 2022, outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview
- Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development
- 13therapeutics Inc
- Acepre LLC
- Akaza Bioscience Ltd
- Allodynic Therapeutics LLC
- Apollo Therapeutics LLC
- AptaTargets SL
- Ayuvis Research Inc
- Celestial Therapeutics Inc
- Douleur Therapeutics Inc
- Edesa Biotech Inc
- EyeGene Inc
- FasCure Therapeutics LLC
- Genesen Co Ltd
- Immunovo BV (Inactive)
- Inimmune Corp
- Kupando GmbH
- Lubris Biopharma
- Merck & Co Inc
- Pattern Pharma Inc
- Protara Therapeutics Inc
- Revelation Biosciences Inc
- Soin Therapeutics LLC
- TaiwanJ Pharmaceuticals Co Ltd
- Vascular Biogenics Ltd
- Xalud Therapeutics Inc
- Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles
- Product Description
- Mechanism Of Action
- History of Events
- ApTOLL - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AVR-48 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Biologic to Agonize TLR4 for Drug Addiction - Drug Profile
- Product Description
- Mechanism Of Action
- Biologics to Antagonize TLR4 for Dengue Fever - Drug Profile
- Product Description
- Mechanism Of Action
- C-34 - Drug Profile
- Product Description
- Mechanism Of Action
- CIA-05 - Drug Profile
- Product Description
- Mechanism Of Action
- CT-02 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DT-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ECF-843 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- G-100 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GS-200 - Drug Profile
- Product Description
- Mechanism Of Action
- INI-2004 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ISAS-01 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KUP-101 - Drug Profile
- Product Description
- Mechanism Of Action
- naltrexone - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- naltrexone hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- naltrexone hydrochloride CR - Drug Profile
- Product Description
- Mechanism Of Action
- P-13 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- P-7 - Drug Profile
- Product Description
- Mechanism Of Action
- P-MAPA - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- P2PAR-100 - Drug Profile
- Product Description
- Mechanism Of Action
- paridiprubart - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PEPA-10 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- resatorvid - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- REVTX-100 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- REVTx-99 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Antagonize TLR4 for Gastrointestinal Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Inhibit TLR2 and TLR4 for Bacterial Sepsis - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Antagonize TLR2 and TLR4 for Pulmonary Edema, Inflammation and Sepsis - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Antagonize TLR4 for Chronic Obstructive Pulmonary Disease, Chronic Asthma and Alzheimer’s Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Antagonize TLR4 for Dengue Fever - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Peptide to Antagonize TLR4 for Sepsis - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Peptide to target TLR-4 for Oncology, Inflammation and Infectious Disease - Drug Profile
- Product Description
- Mechanism Of Action
- TARA-002 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TJC-0133 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VB-201 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VB-703 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- XT-203 - Drug Profile
- Product Description
- Mechanism Of Action
- Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products
- Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products
- Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by 13therapeutics Inc, 2022
- Pipeline by Acepre LLC, 2022
- Pipeline by Akaza Bioscience Ltd, 2022
- Pipeline by Allodynic Therapeutics LLC, 2022
- Pipeline by Apollo Therapeutics LLC, 2022
- Pipeline by AptaTargets SL, 2022
- Pipeline by Ayuvis Research Inc, 2022
- Pipeline by Celestial Therapeutics Inc, 2022
- Pipeline by Douleur Therapeutics Inc, 2022
- Pipeline by Edesa Biotech Inc, 2022
- Pipeline by EyeGene Inc, 2022
- Pipeline by FasCure Therapeutics LLC, 2022
- Pipeline by Genesen Co Ltd, 2022
- Pipeline by Immunovo BV (Inactive), 2022
- Pipeline by Inimmune Corp, 2022
- Pipeline by Kupando GmbH, 2022
- Pipeline by Lubris Biopharma, 2022
- Pipeline by Merck & Co Inc, 2022
- Pipeline by Pattern Pharma Inc, 2022
- Pipeline by Protara Therapeutics Inc, 2022
- Pipeline by Revelation Biosciences Inc, 2022
- Pipeline by Soin Therapeutics LLC, 2022
- Pipeline by TaiwanJ Pharmaceuticals Co Ltd, 2022
- Pipeline by Vascular Biogenics Ltd, 2022
- Pipeline by Xalud Therapeutics Inc, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 13therapeutics Inc
- Acepre LLC
- Akaza Bioscience Ltd
- Allodynic Therapeutics LLC
- Apollo Therapeutics LLC
- AptaTargets SL
- Ayuvis Research Inc
- Celestial Therapeutics Inc
- Douleur Therapeutics Inc
- Edesa Biotech Inc
- EyeGene Inc
- FasCure Therapeutics LLC
- Genesen Co Ltd
- Immunovo BV (Inactive)
- Inimmune Corp
- Kupando GmbH
- Lubris Biopharma
- Merck & Co Inc
- Pattern Pharma Inc
- Protara Therapeutics Inc
- Revelation Biosciences Inc
- Soin Therapeutics LLC
- TaiwanJ Pharmaceuticals Co Ltd
- Vascular Biogenics Ltd
- Xalud Therapeutics Inc
